Abstracts tagged "Disease Activity"

Abstract Number: 713 • 2017 ACR/ARHP Annual Meeting
Long-Term Outcomes in Prolonged Low Disease Activity Are Comparable to Complete Clinical Remission in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Zahi Touma³, Jiandong Su⁴, Nicole Anderson² and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Prolonged clinical remission is a desirable, though rare outcome in systemic lupus erythematosus (SLE). We recently showed that low disease activity (LDA) state confers…
Abstract Number: 1251 • 2017 ACR/ARHP Annual Meeting
Chinese Patient Reported Index with Rheumatoid Arthritis (CPRI-RA): Reliability, Validity and Agreement with DAS28 and HAQ
Man Han¹, Xun Gong¹, Xiao-po Tang¹, Hong-xiao Liu², Jian Liu³, Xin-chang Wang⁴, Jun-li Zhang⁵, Shi Chen⁶, Qing-chun Huang⁷, Yong-fei Fang⁸, Qing-jun Wu⁹, Dong-yi He¹⁰, Zhen-bin Li¹¹, Yue Wang¹², Hong Jiang¹³, Ming-li Gao¹⁴, Wei Liu¹⁵, Ying Liu¹⁶, Ze-guang Li¹⁷, Zhong-wen Zhao¹⁸, Cheng-wu Wang¹⁹, Wei-chao Liu²⁰, Hai-dong Wang²¹, Yu-qian Lou²², Qing-liang Meng²³, Chong-jie Ruan²⁴, Yan-ming Xie²⁵ and Quan Jiang²⁶, ¹Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ²Department of Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ³The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Heifei, China, ⁴Rheumatology, The Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou, China, ⁵Rheumatology, The Fifth Hospital of Xi’an City, Xi’an, China, ⁶Rheumatology, Peking University People's Hospital, Beijing, China, ⁷Rheumatology, Guangzhou Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China, ⁸Rheumatology, Southwest Hospital, Third Military Medical University, chongqing, China, ⁹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ¹⁰Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital, Shanghai, China, ¹¹Rheumatology, Bethune international peace hospital, Shi jiazhuang, China, ¹²Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, China, ¹³Rheumatology, The Ninth People's Hospital of Chongqing City, Chongqing, China, ¹⁴Rheumatology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, ¹⁵Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China, ¹⁶Rheumatology, The Affiliated Hospital of Shangdong University of Traditional Chinese Medicine, Qingdao, China, ¹⁷Rheumatology, The First Affiliated Hospital of Hei Longjiang University of Traditional Chinese Medicine, Ha Erbin, China, ¹⁸Rheumatology, The Second People's Hospital of Fujian Province, Fujian, China, ¹⁹Rheumatology, The First Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China, ²⁰Rheumatology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, China, ²¹Rheumatology, Gansu Provincial Hospital of Traditional Chinese Medicine, Shanxi, China, ²²Henan Rheumatism Hospital, Zhengzhou, China, ²³Rheumatology, Henan Provincial Hospital of Traditional Chinese Medicine, Zhengzhou, China, ²⁴Rheumatology and Pain Management Department, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, China, ²⁵Clinical Evaluation Center, China Academy of Chinese Medical Sciences, Beijing, China, ²⁶Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Background/Purpose: The use of patient reported outcomes(PROs) has become increasingly popular in the chronic disease management, disease monitoring and the assessment of drug efficacy. However,…
Abstract Number: 1553 • 2017 ACR/ARHP Annual Meeting
Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Yujin Park⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: There is a need to better characterize patients with ankylosing spondylitis (AS) who discontinue vs continue TNF inhibitor (TNFi) therapies in real-world clinical settings.…
Abstract Number: 1849 • 2017 ACR/ARHP Annual Meeting
Urinary Epidermal Growth Factor and Monocyte Chemoattractant Protein-1 As Biomarkers of Renal Involvement in ANCA-Associated Vasculitis
Catherine E. Najem¹, Wenjun Ju², Viji Nair², David Cuthbertson³, Rennie L. Rhee¹, Laura Mariani⁴, Simon Carette⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁸, Carol A. McAlear⁹, Paul A. Monach¹⁰, Larry W. Moreland¹¹, Christian Pagnoux⁵, Philip Seo¹², Ulrich Specks¹³, Antoine G. Sreih¹, Steven R. Ytterberg¹⁴, Jeffrey Krischer¹⁵, Matthias Kretzler⁴ and Peter A. Merkel¹⁶, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Michigan, Ann Arbor, MI, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Nephrology, University of Michigan, Ann Arbor, MI, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Boston University School of Medicine, Boston, MA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵University of South Florida, Tampa, FL, ¹⁶Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose :Epidermal growth factor (EGF) mediates distal tubular epithelial cell function and regeneration. Monocyte chemoattractant protein-1 (MCP-1) participates in recruitment of leukocytes to areas of…
Abstract Number: 2372 • 2017 ACR/ARHP Annual Meeting
Obesity and the Impact on Treat to Target Goals and Functional Ability in RA. Results from Two Multi-Centre UK Inception Cohorts
Elena Nikiphorou¹, Sam Norton², Patrick Kiely³ and Adam Young⁴, ¹Academic Rheumatology Department, King's College London, London, United Kingdom, ²Academic Rheumatology, King´s College London, London, United Kingdom, ³St George's Hospital, London, United Kingdom, ⁴University of Hertfordshire, Hertford, United Kingdom
Background/Purpose: The links between inflammation, obesity and joint dysfunction are well established. How these translate into clinical disease activity and functional disability in rheumatoid arthritis…
Abstract Number: 2625 • 2017 ACR/ARHP Annual Meeting
Predicting Flares in Patients with Stable Systemic Lupus Erythematosus
Jiacai Cho¹, Manjari Lahiri¹, Lay Kheng Teoh¹, Preeti Dhanasekaran^2,3, Pak Moon Peter Cheung¹ and Aisha Lateef¹, ¹Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ²National University of Singapore, singapore, Singapore, ³National University Hospital of Singapore, Singapore, Singapore
Background/Purpose: The course of systemic lupus erythematosus (SLE) varies with periods of quiescence punctuated by flares. Predicting exacerbations allows clinicians to select patients who need…
Abstract Number: 2964 • 2017 ACR/ARHP Annual Meeting
Structural Damage in Patients with Very Early RA Is Predicted with Clinical Measures of Baseline Disease Activity: DAS28 (CRP), SDAI, M-DAS28 and RAPID3 but Not CDAI
Edward C. Keystone¹, H Ahmad², Yusuf Yazici³, X Liu² and MJ Bergman⁴, ¹University of Toronto, Toronto, ON, Canada, ²Bristol-Myers Squibb, Princeton, NJ, ³New York University School of Medicine, New York, NY, ⁴Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: Clinicians rely on time-efficient, validated disease activity assessments to help accurately predict disease progression in patients with RA. The utility of the Routine Assessment…
Abstract Number: 366 • 2017 ACR/ARHP Annual Meeting
Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom
Lianne Kearsley-Fleet¹, Diederik De Cock¹, Eileen Baildam², Michael W. Beresford³, Helen E. Foster⁴, Taunton R. Southwood⁵, Wendy Thomson^6,7 and Kimme L. Hyrich^1,6, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴Institute of Cellular Medicine and Paediatric Rheumatology, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁵Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁶National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) comprises 7 ILAR categories, but systemic-onset JIA (sJIA) appears to be distinct in genetic background and pathogenesis from the other…
Abstract Number: 789 • 2017 ACR/ARHP Annual Meeting
Markers of Inflammation and Patient-Reported Measures As Predictors of Relapse in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine G. Sreih², Gunnar Tomasson³, David Cuthbertson⁴, Renee Borchin⁵, Simon Carette⁶, Lindsy J. Forbess⁷, Nader A. Khalidi⁸, Curry L. Koening⁹, Carol A. McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Christian Pagnoux⁶, Philip Seo¹³, Robert F. Spiera¹⁴, Kenneth J. Warrington¹⁵, Steven R. Ytterberg¹⁵, Carol A. Langford¹⁶ and Peter A. Merkel^17,18, ¹Rheumatology, University of California Los Angeles, Los Angeles, CA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Iceland, Faculty of Medicine, Reykjavik, IS, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵University of South Florida, Tampa, FL, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatology, McMaster University, Hamilton, ON, Canada, ⁹Rheumatology, University of Utah, Salt Lake City, UT, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Boston University School of Medicine, Boston, MA, ¹²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Medicine, Johns Hopkins University, Baltimore, MD, ¹⁴Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁵Rheumatology, Mayo Clinic, Rochester, MN, ¹⁶Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The significance of increasing erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in clinically asymptomatic individuals with giant cell arteritis (GCA) is controversial. Patient-reported…
Abstract Number: 1265 • 2017 ACR/ARHP Annual Meeting
Impaired Cardiac Function in Juvenile Mixed Connective Tissue Disease Compared with Controls
Birgit Nomeland Witczak¹, Siri Opsahl Hetlevik², Zoltan Barth^1,3, Thomas Schwartz^4,5, Berit Flatø^2,6, Vibke Lilleby^2,6 and Ivar Sjaastad^1,6,7, ¹Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ³Department of Pathophysiology and Gerontology, Medical School, University of Pècs, Pècs, Hungary, Pècs, Hungary, ⁴Oslo University Hospital and University of Oslo, Institute for Experimental Medical Research, Oslo, Norway, ⁵Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ⁷Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Juvenile MCTD (JMCTD) is a heterogenic autoimmune disease, with SLE-, SSc- and PM/DM and RA like manifestations. Cardiac involvement is known in juvenile SLE,…
Abstract Number: 1555 • 2017 ACR/ARHP Annual Meeting
Treatment Changes By Joint Activity and Skin Severity in Patients with Comorbid Psa and Pso
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Treatment of both joint and skin symptoms is important for overall disease management of patients with psoriatic arthritis and comorbid psoriasis1,2. The objective of…
Abstract Number: 1879 • 2017 ACR/ARHP Annual Meeting
Majority of Rheumatoid Arthritis Patients in Clinical Remission As Defined By DAS-28, CDAI, SDAI and RAPID-3 Have No Signal on Ultrasound Power Doppler
Allen P. Anandarajah¹, Andreea Coca² and Ralf G. Thiele³, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Remission in rheumatoid arthritis (RA) is often assessed using the following indices: disease activity scores (DAS-28), clinical disease activity index (CDAI), Simplified Disease Activity…
Abstract Number: 2374 • 2017 ACR/ARHP Annual Meeting
Obesity Impacts ESR and Not Other Measures of Rheumatoid Arthritis Disease Activity
Ana Maheshwari¹, Oumoul Barry¹ and MJ Bergman², ¹Internal Medicine, Mercy Catholic Medical Center, Darby, PA, ²Medicine, Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: Disease activity measurement is a cornerstone to treat to target strategy. The impact of body mass index (BMI) on disease activity in rheumatoid arthritis…
Abstract Number: 2641 • 2017 ACR/ARHP Annual Meeting
Immune Complex-Driven Neutrophil Activation in Systemic Lupus Erythematosus – Novel Biomarkers of Disease Activity and Severity
Hsin-Hsuan Juo¹, Edward Chiou², Keith B. Elkon³ and Christian Lood⁴, ¹Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Department of Medicine & Immunology, University of Washington, Seattle, WA, ⁴Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Neutrophil activation is linked to inflammation and autoimmune diseases, including systemic lupus erythematosus (SLE) where nucleic acid-containing immune complexes (ICs) drive inflammation through engagement…
Abstract Number: 2968 • 2017 ACR/ARHP Annual Meeting
Less Fatigue in Psoriatic Arthritis after High Intensity Interval Training. a Randomized Controlled Trial
Ruth Stoklund Thomsen¹, Tom Ivar Lund Nilsen², Glenn Haugeberg³, Anja Bye³, Arthur Kavanaugh⁴ and Mari Hoff⁵, ¹Faculty of Medicine, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ²Faculty of medicine, Department of public health and nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ³NTNU, Norwegian University of Science and Technology, Trondheim, Norway, ⁴Medicine, University of California, San Diego, La Jolla, CA, ⁵Rheumatolgy, University Hospital, St. Olavs Hospital, NTNU, Trondheim, Norway
Background/Purpose: Patients with psoriatic arthritis (PsA) have a high disease burden with increased pain and more fatigue than the general population. Physical exercise is recommended…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].